Promising early results regarding the use of litifilimab in patients with CLE were presented as part of a late-breaking session at the 2026 AAD Annual Meeting.

Patients with ophiasis may be categorized into 3 distinct subtypes that can guide early intervention and stratify treatment.

Blaine Labs recalls Revitaderm and Tridergel wound care gels due to microbial contamination with Lysinibacillus fusiformis.

After months of leadership changes, President Donald Trump has chosen a new candidate to lead the U.S. Centers for Disease Control and Prevention (CDC). The White House announced Thursday that Dr.

Close to 90% of adults in the United States reported having a source of usual health care in 2024, with differences seen by age and sex.

Chatbots or other AI tools were used by around 1 in 4 American adults seeking physical or mental health information.

Real-world data on spesolimab have shown rapid improvement in acute flares of GPP, along with a favorable safety profile, according to a systemic review.

Superior efficacy and comparable safety was seen with DFD-29 in patients with rosacea when compared with the current first-line systemic.

The TrumpRx site now lists more than 61 discounted medications from 11 drugmakers, up from about 40 when it launched in February.

Moderate to severe glabellar lines may be effectively and safely treated with YY001, a new recombinant botulinum toxin type A product.

Despite the initiation of a phase 3 confirmatory trial, the FDA remains unsatisfied with the interpretability of phase 2 data for Replimune’s oncolytic immunotherapy.

Circulating tumor HPV DNA levels were linked to clinical risk in patients having surgery for HPV-related oropharyngeal cancer.